KRAS and colorectal carcinoma: Notably, the finding is also supported by the analysis of Medico 113 CMS1-4 CRC cell lines (Fig. 8e) among which HCT116 (CMS4, KRAS G13D) and LIM2405 (CMS1, BRAF (V600E) (both within Fig. 8e RUQs) were shown to be sensitive to MEKi + SRCi in vitro (Additional File 3_Fig S10 and S11).